Floatz logo

Siltuximab

Smoldering Plasma Cell Myeloma

Janssen Research & Development, LLCmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Smoldering Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Dexasone
Regeneron Pharmaceuticals
Phase 3BB
Nivestim
Regeneron Pharmaceuticals
Phase 3BB
Lenalidomide
Irene Ghobrial, MD
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
Daratumumab
Regeneron Pharmaceuticals
Phase 3BB

View all 47 →

Same molecule, other indications

Siltuximab is also rated in:

plasma cell myelomaActive
B
Indicative · Phase 3
62 / 100
View asset →
cytokine release syndromeActive
B
Indicative · Phase 2
61 / 100
View asset →
non-Hodgkin lymphomaActive
B
Indicative · Phase 2
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →